Rapid Dose Therapeutics Corp. (CSE: DOSE) (OTCQB: RDTCF) has announced a proposed shares-for-debt transaction with certain creditors, seeking to cancel up to $500,000 in outstanding accounts payable by issuing up to 5,000,000 common shares. The Burlington, Ontario-based biotechnology company is aiming to strengthen its balance sheet by reducing existing liabilities. The transaction remains subject to acceptance by the Canadian Securities Exchange, making regulatory approval a near-term milestone for investors to monitor.

Key Points

  • Rapid Dose Therapeutics Corp. (CSE: DOSE) (OTCQB: RDTCF)
  • The company proposes to issue up to 5,000,000 common shares to settle up to $500,000 in accounts payable owed to certain creditors
  • Settlement shares will be priced at $0.10 each; Canadian resident recipients face a four-month hold period from the date of issuance
  • Investors should watch for CSE acceptance of the transaction before it can be completed

Shares-for-Debt Structure and Settlement Terms

Under the proposed Shares for Debt Transaction, Rapid Dose Therapeutics has agreed with certain creditors to issue up to an aggregate of 5,000,000 common shares at a price of $0.10 per share, in accordance with CSE policies. In exchange, those creditors would cancel outstanding accounts payable totalling up to $500,000. The release states that no new control person of the company will be created as a result of the transaction. Settlement shares issued to Canadian residents will be subject to a four-month hold period calculated from the date of issuance.

Balance Sheet Rationale Behind the Debt Reduction Move

The company states it is completing the Shares for Debt Transaction to improve its financial position by reducing its existing liabilities. By converting accounts payable into equity rather than repaying creditors in cash, Rapid Dose Therapeutics preserves working capital that could otherwise be directed toward operations. This type of non-cash settlement is a common tool among smaller public companies managing liquidity. The company did not disclose the total number of creditors participating or the breakdown of individual debt amounts being settled through the announcement.

QuickStrip™ Drug Delivery Platform and Company Background

Rapid Dose Therapeutics describes itself as a Canadian biotechnology company focused on drug delivery innovation. Its flagship product, QuickStrip™, is a thin, orally dissolvable film that can be infused with nutraceuticals, pharmaceuticals, or vaccines, designed to deliver active ingredients rapidly into the bloodstream. The company notes that in a recent separate announcement, it shipped a QuickStrip™ production line to a Texas cGMP facility operated by Callan JMB, reflecting ongoing commercial activity alongside the proposed financial restructuring.